Xanomeline (LY246708) Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease H2Q-MC-LZZT(c) A randomized, double-blind, parallel (3 arm), placebo-controlled trial of 26 weeks duration. Indication ASTHMA Screening Epoch Treatment Epoch Follow-Up Epoch Placebo arm Low-dose xanomeline arm (50cm^2 TTS Formulation E, 54 mg xanomeline) High-dose xanomeline arm (75cm^2 TTS Formulation E, 81 mg xanomeline) Screening cell Treatment cell Screening segment/period Treatment segment/period Treatment segment/period Collection of Informed Consent Assignation of Study Participant ID Collection of Medical History Collection of Vital Signs: Pre-Ambulatory-ECG Placement of Ambulatory ECG Removal of Ambulatory ECG Collection of Vital Signs: Post-Ambulatory-ECG Randomization of the PAtient to a Trial Arm Screening Visit 24-Hour Ambulatory ECG Applied ECG Removal, Randomization ECG Results Vital Signs Measurements Over Age 21 Age > 21 Informed Consent Granted Consented = 'true'